26 research outputs found
Short-chain fatty acid propionate protects from hypertensive cardiovascular damage
BACKGROUND: Arterial hypertension and its organ sequelae show characteristics of T cell mediated inflammatory diseases. Experimental anti-inflammatory therapies have been shown to ameliorate hypertensive end-organ damage. Recently, the CANTOS study targeting interleukin-1Ξ² demonstrated that anti-inflammatory therapy reduces cardiovascular risk. The gut microbiome plays pivotal role in immune homeostasis and cardiovascular health. Short-chain fatty acids (SCFA) are produced from dietary fiber by gut bacteria and affect host immune homeostasis. Here, we investigated effects of the SCFA propionate in two different mouse models of hypertensive cardiovascular damage. METHODS: To investigate the effect of SCFA on hypertensive cardiac damage and atherosclerosis, wild-type NMRI (WT) or ApoE(-/-) deficient mice received propionate (200mM) or control in the drinking water. To induce hypertension, WT mice were infused with Angiotensin (Ang)II (1.44mg/kg/d s.c.) for 14 days. To accelerate the development of atherosclerosis, ApoE(-/-) mice were infused with AngII (0.72mg/kg/d s.c.) for 28 days. Cardiac damage and atherosclerosis were assessed using histology, echocardiography, in vivo electrophysiology, immunofluorescence, and flow cytometry. Blood pressure was measured by radiotelemetry. Regulatory T cell (Treg) depletion using PC61 antibody was used to examine the mode of action of propionate. RESULTS: Propionate significantly attenuated cardiac hypertrophy, fibrosis, vascular dysfunction, and hypertension in both models. Susceptibility to cardiac ventricular arrhythmias was significantly reduced in propionate-treated AngII-infused WT mice. Aortic atherosclerotic lesion area was significantly decreased in propionate-treated ApoE(-/-). Systemic inflammation was mitigated by propionate treatment, quantified as a reduction in splenic effector memory T cell frequencies and splenic T helper 17 cells in both models, and a decrease in local cardiac immune cell infiltration in WT mice. Cardioprotective effects of propionate were abrogated in Treg-depleted AngII-infused mice, suggesting the effect is Treg-dependent. CONCLUSIONS: Our data emphasize an immune-modulatory role of SCFAs and their importance for cardiovascular health. The data suggest that lifestyle modifications leading to augmented SCFA production could be a beneficial non-pharmacological preventive strategy for patients with hypertensive cardiovascular disease
SLM von Polylactiden zur Herstellung von resorbierbaren Implantaten
Rapid Manufacturing von individuellen Implantaten mittels Selective Laser Melting (SLM) wurde fΓΌr metallische Standardwerkstoffe in der Medizintechnik (Titanlegierungen, Kobalt-Chrom-Legierungen, Stahl) realisiert. Dies sind permanente Implantate, die entweder dauerhaft im KΓΆrper verbleiben oder in einer zweiten Operation entfernt werden. Eine vom ILT mittels SLM hergestellte HΓΌftpfanne aus TiAl6V4 konnte bereits erfolgreich im Patienten implantiert werden. Die regenerative Therapie ist jedoch die klinisch bevorzugte Strategie. Das bedeutet, dass der Selbstheilungsprozess des menschlichen KΓΆrpers fΓΌr die Heilung von groΓen Knochendefekten genutzt wird. Ein neuer Ansatz zur Implantatfertigung folgt dieser Strategie. Der SLM-Prozess wird fΓΌr die Verarbeitung von bioresorbierbaren Werkstoffen entwickelt um individuelle Implantate zu fertigen, die im KΓΆrper abgebaut und durch kΓΆrpereigenes Knochengewebe ersetzt werden. Diese Arbeit beschreibt die Qualifizierung des SLM Verfahrens fΓΌr die Verarbeitung von einem Kompositmaterial aus Polylactid / Ξ²-Tricalciumphosphat (PDLLA/Ξ²-TCP).Rapid Manufacturing of individual implants using SLM was realized for standard materials in medical technology (Titaniumalloys, cobalt-chromium-alloys, steel). Theses are permanent implants which will stay in the body or will be removed in a second surgery. At Fraunhofer ILT an acetabulum cup was manufactured out of TiAl6V4 using SLM. The cup was successfully implanted in the patient. The regenerative therapy is the clinically preferred strategy. The self-regeneration process of the human body is used to heal bone defects. A new approach follows this strategy. The SLM technology is developed to process bioabsorbable materials. Using additive manufacturing individual implants can be manufactured which will dissolve in the body and will be replaced by human bone. This work describes the development of the process technology to manufacture implants with defined porosity out of a composite material polylactide and Ξ²-tricalciumphosphate (PLLA/Ξ²-TCP)
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ Π½ΠΎΠ²ΡΡ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΠΉ: ΡΠ±ΠΎΡΠ½ΠΈΠΊ Π½Π°ΡΡΠ½ΡΡ ΡΡΡΠ΄ΠΎΠ² II ΠΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ»ΠΎΠ΄Π΅ΠΆΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ½Π³ΡΠ΅ΡΡΠ°, Π³. Π’ΠΎΠΌΡΠΊ, 30 ΡΠ΅Π½ΡΡΠ±ΡΡ - 5 ΠΎΠΊΡΡΠ±ΡΡ 2019 Π³.
Π ΡΠ±ΠΎΡΠ½ΠΈΠΊΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ Π΄ΠΎΠΊΠ»Π°Π΄ΠΎΠ² ΠΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠΉ Π½Π°ΡΡΠ½ΠΎ-ΡΠ΅Ρ
Π½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΌΠΎΠ»ΠΎΠ΄Π΅ΠΆΠ½ΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅ΡΠ΅Π½ΡΠΈΠΈ Β«ΠΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠ΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΊΠΎΠ½ΡΡΡΡΠΊΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΈ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡΒ» ΠΈ VIII ΠΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠΉ Π½Π°ΡΡΠ½ΠΎ-ΡΠ΅Ρ
Π½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅ΡΠ΅Π½ΡΠΈΠΈ ΠΌΠΎΠ»ΠΎΠ΄ΡΡ
ΡΡΠ΅Π½ΡΡ
, Π°ΡΠΏΠΈΡΠ°Π½ΡΠΎΠ² ΠΈ ΡΡΡΠ΄Π΅Π½ΡΠΎΠ² Β«ΠΡΡΠΎΠΊΠΈΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ Π² ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ Π½Π°ΡΠΊΠ΅ ΠΈ ΡΠ΅Ρ
Π½ΠΈΠΊΠ΅Β». Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π²ΠΎΠ·Π½ΠΈΠΊΠ°Π΅Ρ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠΈΠ½ΡΠΈΠΏΠΈΠ°Π»ΡΠ½ΠΎ Π½ΠΎΠ²ΡΡ
ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΎΠ² ΠΊ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΊΠΎΠ½ΡΡΡΡΠΊΡΠΈΠΎΠ½Π½ΡΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ², ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΈ Π½ΠΎΠ²ΡΡ
ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π΅Π½Π½ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ. Π Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ Π½Π° ΠΏΡΡΠΈ Π³Π»ΡΠ±ΠΎΠΊΠΎΠΉ ΠΈΠ½ΡΠ΅Π³ΡΠ°ΡΠΈΠΈ ΡΡΠ½Π΄Π°ΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π°ΡΠΊΠΈ ΠΈ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Ρ ΡΠΈΡΠΎΠΊΠΈΠΌ ΠΏΡΠΈΠ²Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΠΌ Π½Π°ΡΡΠ½ΠΎΠΉ ΠΌΠΎΠ»ΠΎΠ΄Π΅ΠΆΠΈ ΠΎΡ ΡΡΡΠ΄Π΅Π½ΡΠΎΠ² Π΄ΠΎ Π°ΡΠΏΠΈΡΠ°Π½ΡΠΎΠ². Π Π°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π»ΠΈΡΡ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ: Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ Π±ΠΈΠΎΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ; ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΈΡΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΈ ΡΠ΅Ρ
Π½ΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΡΡΡ ΠΈ Π²ΠΎΠ΄Π½ΡΡ
ΡΠ΅ΡΡΡΡΠΎΠ²; ΡΠΎΡΠΎΠ½Π½ΡΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΡΠ²Π΅ΡΠΎΠ²Π°Ρ ΠΈΠ½ΠΆΠ΅Π½Π΅ΡΠΈΡ; ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π½Π°Π΄Π΅ΠΆΠ½ΠΎΡΡΠΈ ΠΌΠ°ΡΠΈΠ½ΠΎΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΈ ΠΌΠ°ΡΠΈΠ½ΠΎΡΡΡΠΎΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ. Π¦Π΅Π»ΡΡ ΠΊΠΎΠ½Π³ΡΠ΅ΡΡΠ° ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΊΠΎΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ ΡΠΎΡΡΠΈΠΉΡΠΊΠΈΡ
ΠΈ Π·Π°ΡΡΠ±Π΅ΠΆΠ½ΡΡ
ΠΌΠΎΠ»ΠΎΠ΄ΡΡ
ΡΡΠ΅Π½ΡΡ
ΠΈ ΡΡΡΠ΄Π΅Π½ΡΠΎΠ² Π² ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠΈ Π½Π°ΡΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π² ΠΎΠ±Π»Π°ΡΡΠΈ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
Π²ΡΡΠΎΠΊΠΈΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ. Π‘Π±ΠΎΡΠ½ΠΈΠΊ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ Π΄Π»Ρ ΡΡΡΠ΄Π΅Π½ΡΠΎΠ², Π°ΡΠΏΠΈΡΠ°Π½ΡΠΎΠ² ΠΈ ΠΌΠΎΠ»ΠΎΠ΄ΡΡ
ΡΡΠ΅Π½ΡΡ
, ΠΈΠ½ΡΠ΅ΡΠ΅ΡΡΡΡΠΈΡ
ΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ°ΠΌΠΈ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ, Π½ΠΎΠ²ΡΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² ΠΈ ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΈΡΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΡΡΡΡ